Cabergoline versus levodopa monotherapy: a decision analysis.

about

The use of decision-analytic models in Parkinson's disease: a systematic review and critical appraisal.Modelling the cost effectiveness of treatments for Parkinson's disease: a methodological review.

P2860

Q37891050-6FA1F71E-F03E-4E24-96A0-2528AA08C0A1 Q37955238-7DF9F2AA-FF5F-4C86-B9AF-B7FF69284995

P2860

Cabergoline versus levodopa monotherapy: a decision analysis.

Item

http://www.wikidata.org/entity/Q44531222

description

2003 nî lūn-bûn

@nan

2003年の論文

@ja

2003年学术文章

@wuu

2003年学术文章

@zh

2003年学术文章

@zh-cn

2003年学术文章

@zh-hans

2003年学术文章

@zh-my

2003年学术文章

@zh-sg

2003年學術文章

@yue

2003年學術文章

@zh-hant

name

Cabergoline versus levodopa monotherapy: a decision analysis.

@en

Cabergoline versus levodopa monotherapy: a decision analysis.

@nl

type

Item

label

Cabergoline versus levodopa monotherapy: a decision analysis.

@en

Cabergoline versus levodopa monotherapy: a decision analysis.

@nl

prefLabel

Cabergoline versus levodopa monotherapy: a decision analysis.

@en

Cabergoline versus levodopa monotherapy: a decision analysis.

@nl

P1476

Cabergoline versus levodopa monotherapy: a decision analysis.

@en

P2093

Antje M Smala

http://www.w3.org/2001/XMLSchema#string

Dieter Meyer

http://www.w3.org/2001/XMLSchema#string

E Annika Spottke

http://www.w3.org/2001/XMLSchema#string

Janeen DuChane

http://www.w3.org/2001/XMLSchema#string

Karin B Berger

http://www.w3.org/2001/XMLSchema#string

Martin Reuther

http://www.w3.org/2001/XMLSchema#string

Olaf Machat

http://www.w3.org/2001/XMLSchema#string

Richard C Dodel

http://www.w3.org/2001/XMLSchema#string

Rudolf Köhne-Volland

http://www.w3.org/2001/XMLSchema#string

Uwe Siebert

http://www.w3.org/2001/XMLSchema#string

P2860

Cost effectiveness of pramipexole in Parkinson's disease in the US.

A randomised controlled study comparing bromocriptine to which levodopa was later added, with levodopa alone in previously untreated patients with Parkinson's disease: a five year follow up.

Parkinson disease survival: a population-based study.

Continuous dopamine-receptor stimulation in advanced Parkinson's disease.

Continuous dopamine-receptor stimulation in early Parkinson's disease.

Cost per millimeter of mercury lowering is a measure of economic value for antihypertensive agents.

Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature.

An algorithm (decision tree) for the management of Parkinson's disease (2001): treatment guidelines.

Cost-effectiveness of pergolide compared to bromocriptine in the treatment of Parkinson's disease: a decision-analytic model.

The sydney multicentre study of Parkinson's disease: progression and mortality at 10 years

P304

898-905

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/MDS.10465

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Wolfgang H. Oertel

P577

2003-08-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

12889079

http://www.w3.org/2001/XMLSchema#string

P921

levodopa

Cabergoline versus levodopa monotherapy: a decision analysis.

about

P2860

P2860

Cabergoline versus levodopa monotherapy: a decision analysis.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698

P921

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698

P921